Navigation Links
OncoGenex Reports Third Quarter Financial Results
Date:11/4/2010

lidated Balance Sheets

(in thousands) September 30, December 31,   2010 2009   (unaudited)   Assets:   Cash, cash equivalents and short term investments $42,067   $ 64,568   Restricted cash 502 —    Amounts receivable 3,595 3,109   Prepaid expenses 1,03
722   Property, equipment and other assets 579 581 Total assets 47,773
$ 68,980 Liabilities and stockholders' equity:   Accounts payable and accrued liabilities 2,123
$ 14,453   Deferred collaboration revenue 23,043 26,528   Current portion of long-term obligations 1,344 1,328   Long term obligation 6,960 3,712   Shareholders' equity 14,303 22,959 Total liabilities and shareholders' equity 47,773
$ 68,980

'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
2. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
3. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
4. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
5. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
6. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
7. OncoGenex Reports Second Quarter Financial Results
8. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
9. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
10. OncoGenex Reports First Quarter Financial Results
11. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... NJ (PRWEB) October 22, 2014 ... and services – has been working with a team ... and New Haven Farms Community Farming Collaborative to provide ... ePRO solution. The study, which started in May, ... program that provides participants weekly exposure to and participation ...
(Date:10/22/2014)... 22, 2014   Synthetic Biologics, Inc. (NYSE ... for serious infections and diseases, announced today that the ... of Allowance for a composition of matter patent application ... program, SYN-004. This is Synthetic Biologics, first allowed ... and adds to the Company,s extensive C. difficile ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... , October 20, 2014 ... gastrointestinal (GI) disorders and the delivery of care has ... diseases and worrying inequalities in the provision of healthcare ... which was commissioned by United European Gastroenterology (UEG), have ... political and public awareness of the burden of GI ...
Breaking Biology Technology:myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... Calif., Aug. 7 ISTA Pharmaceuticals,Inc. (Nasdaq: ISTA ), ... 2008. ISTA reported net revenue of $17.8 million for the,quarter ... quarter of 2007.,The net loss for the second quarter ended ... compared with a net loss of $8.7 million (or $0.32,per ...
... /PRNewswire-FirstCall/ - Chromos Molecular,Systems Inc. ("Chromos" or the ... arrangement agreement (the "Arrangement Agreement") dated,August 6, 2008 ... subsidiary of Chromos, and Modatech Systems Inc. ("Modatech"),pursuant ... agreed to effect a plan,of arrangement (the "Arrangement") ...
... in Health Sciences and Photonics, today announced that its analytical ... Food Safety Monitoring (BFSM) in a mobile laboratory supporting the ... for volatile organic compounds in beverages and pesticides in food ... ...
Cached Biology Technology:ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 2ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 3ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 4ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 5ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 6ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results 7Chromos enters into an Arrangement Agreement 2Chromos enters into an Arrangement Agreement 3 PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory 2 PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory 3
(Date:10/16/2014)... constantly wages war on the human body. Battles ... stalemate. In pancreatic cancer, this stalemate—known as tumor ... aggressively malignant, a phenomena that is poorly understood. ... the laboratory of Salvatore Torquato, a Professor of ... conditions surrounding tumor dormancy and the switch to ...
(Date:10/16/2014)... and Washington land managers have a new synthesis of ... moist mixed-conifer (MMC) forests in the two states. ... in Eastern Oregon and Washington: A Synthesis of the ... a general technical report published by the U.S. Forest ... to a request from managers for a synthesis of ...
(Date:10/16/2014)... efficiently, they are anything but sustainable: environmental damage ... is becoming increasingly evident. Despite their disadvantages, however, ... regarded as the sole possibility of achieving higher ... Bernhard Schmid, an ecology professor at the University ... agriculture and forestry. After all, a new study ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2New report synthesizes best available science on management of moist mixed-conifer forests 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3
... using highly sophisticated equipment. Yet the Florida State University geochemist ... Tibet and camping in the foothills of the Himalayas ... that unique mix of skills, Wang was chosen to take ... prehistoric woolly rhino ever found. A paper describing the team,s ...
... WASHINGTON, D.C. The American Association for Cancer ... Science of Cancer Health Disparities from Sept. 18-21, 2011, ... This conference will bring together scientists, survivors, ... cancer genetics, epidemiology and treatment methods to better meet ...
... pheromone-baited bucket traps, canines to sniff out breeding sites, ... the coconut rhinoceros beetle (CRB) on Guam with the ... tactics. USDA has given Guam an infusion of cash ... population on island. Aubrey Moore, entomologist and researcher with ...
Cached Biology News:A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 2A wild and woolly discovery: FSU scientist's Tibetan expedition ends with prehistoric find 3AACR to host conference on the science of cancer health disparities 2
Mouse monoclonal antibody to ACP2 - acid phosphatase 2, lysosomal...
... platform, 220 V, is used for agitation and ... cultures, staining and destaining of gels and blots, ... control (8-40 rpm) and can handle a maximum ... features two 29 x 21 cm platforms covered ...
... 2,2′-Azino- bis (3-ethylbenzthiazoline-6-sulfonic Acid) Clear ... of ABTS and H 2 O 2 ... stabilizers. Peroxidase substrate that is soluble, safe, convenient ... ™ develops intense blue-green color that can ...
...
Biology Products: